Regulatory CD4 + T cells (Tregs) are pivotal for prevention of autoimmunity. The use of Tregs is therefore of increasing interest in in vitro drug screening assays as well as for a cytotherapy per se against autoimmune disorders. For both purposes, in vitro expansion of peripheral blood Tregs is necessary and there is an increasing need to identify novel markers that can discriminate natural thymicderived Tregs (tTregs) from other T cell subsets, and ideally, such markers should be stably expressed during in vitro expansion procedures. We screened for novel miRNAs differentially expressed in tTregs and identified miR-146a and 142-3p as possible candidates. We analysed freshly isolated na€ ıve and activated tTregs and non-Treg subsets after or prior to in vitro expansion. We observed a tTreg-specific profile of these miRNAs together with FOXP3 and Helios in freshly isolated tTregs, but observed a decline in the same markers in activated tTregs as opposed to na€ ıve tTregs. In vitro-expanded Tregs could be identified based on FOXP3 expression, but with loss of a discriminate profile for miRNA candidates and a decline in FOXP3 when activated tTregs were expanded. Our data demonstrate miR-146a and 142-3p as potential miRNA markers for discrimination between non-Treg cells and tTregs, but these miRNAs are not stable markers for in vitro-expanded Treg cells. In addition, the loss of FOXP3 in expansion of activated tTregs has implication for in vitro use of this cell subset in immunopharmacological assays and cytotherapy as FOXP3 is pivotal for suppressive function.
Introduction
Regulatory T cells (Tregs) are specialized CD4 + T helper cells that play a key role in maintaining peripheral tolerance to self-antigens. Thus, the dysfunction of these cells has been implicated in many autoimmune and chronic inflammatory disorders, and likewise, they have been shown to be involved in cancer-mediated immunosuppression. The majority of circulating Tregs are thymus-derived Tregs (tTregs), but they can also develop in the periphery from na€ ıve CD4 + T cells and are then designated peripherally derived Tregs (pTregs) [1] .
Treg cells are characterized by high expression of the transcription factor FOXP3 which plays a central role in the differentiation and function of these cells [1] . However, several other markers have been suggested that in combination may discriminate different Treg subsets and function. One example is Helios, a marker of tTregs recently derived from the thymus and therefore na€ ıve tTregs [2] . Also, na€ ıve and activated tTregs can be separated based on the expression of CD45RA in CD4 + CD25 high CD127 dim/À cells [3] . However, since many Treg markers are not completely unique for Treg cells, additional and more specific markers are still searched for to identify subsets of tTregs based on function and developmental stage in the immune system [4] .
MicroRNAs (miRNAs) are short non-coding RNAs that negatively regulate gene expression at a posttranscriptional stage through inhibition of translation and the subsequent degradation of the target mRNA [5] . MicroRNAs are also important for the development and function of Tregs, for example, demonstrated by the inhibition of Tregs in mice with conditional knockout of Dicer [6] . MiRNA expression is increasingly used for identification of specific subsets of cell populations, and recently, several publications have also elucidated specific roles for miRNAs in Tregs. In example, miR-15b/16, miR-24 and miR-29a have been shown to regulate induction of Tregs from na€ ıve CD4 + T cells [7] , miR-146a and 155 may influence the Treg phenotype [8] [9] [10] , and the miRNA profile has been suggested to discriminate na€ ıve from memory Tregs [11] and disease-specific Treg phenotypes [12] . Thus, research is still ongoing with the purpose of identifying Treg-specific miRNAs that are also stable in different Treg phenotypes [4] .
The use of tTregs is being increasingly implemented in in vitro functional pharmacological assays that assess the anti-inflammatory capacity of novel drug compounds and the direct effect on Tregs [13] . Also, cytotherapy that takes advantage of isolated tTregs and the infusion of such into patients with severe chronic inflammation is a promising therapy [14] . However, due to the low frequency of tTregs cells in peripheral blood, in vitro expansion is necessary for both purposes. For this procedure, choosing the correct tTreg subtype is important; that is, the loss of FOXP3 is more pronounced in expanded CD45RA activated tTreg cells as compared to expanded CD4 + CD25 high CD127
dim/ À CD45RA + na€ ıve tTreg cells, and in addition, expanded activated tTregs may become apoptotic [15] . We and others recently demonstrated the stable inhibitory capacity of expanded na€ ıve tTregs [3, 13] ; however, validation of such expanded cells with reliable biomarkers for the suppressive tTreg phenotype of expanded cells is important and can potentially be performed by analysis of classical tTreg markers combined with novel tTreg-defining miRNAs.
Here, we describe a procedure for FACS sorting of CD4 + CD25 high CD127 dim/À CD45RA + na€ ıve vs CD45RA-activated tTreg cells and analyse the expression of the tTreg markers Foxp3 and Helios. Following screening of tTregspecific miRNAs, we investigated the expression of miR146a and 142-3p and compared expression levels between tTregs and non-Tregs as well as between na€ ıve and activated tTregs before and after expansion procedures.
Materials and methods
T cell isolation. Buffy coats from healthy donors were supplied from the department of clinical immunology at Rigshospitalet in Copenhagen, Denmark, which hold the approval for use of blood products for research purposes. Donors were between the age 18 and 50, without recent medication and with assigned consent. Peripheral blood mononuclear cells (PBMC) were isolated by gradient centrifugation on Lymphoprep (Nycomed, Oslo, Norway), and the isolated cells were pre-enriched for CD4 T lymphocytes (BD IMag TM Human CD4 T cell Lymphocyte Enrichment set; BD Biosciences, Albertslund, Denmark). Cell isolation was performed in RPMI medium (Lonza) containing 2 nM L-glutamine, 1% MEM vitamins, 1 mM natrium pyrovat, 1% MEM NEAA, 10 mM HEPES, 100 U/ml penicillin, 100 lg/ml streptomycin, 50 lM 2-mercaptoethanol and 10% heat-inactivated human AB serum (Lonza). Briefly, a negative selection of CD4 T lymphocytes from PBMCs was performed using BD IMagnet according to the accompanying protocol. CD4-enriched lymphocytes were stained by use of Human Regulatory T cell sorting kit (BD Biosciences) according to the manufacture's description. The kit provides reagents that allow staining for CD4 + CD25 + CD127lo CD45RA
+/À tTreg cells. Stained cells were filtered through a 30-lm mesh filter and resuspended in FACS buffer at a cell density of 10 9 10 6 cells/ml. The tTreg cells and conventional T cells, CD4 + CD25-used as controls, were sorted on a BD FACSAria III sorter using a 70-lm nozzle. Sorted cells were collected in tubes with complete RPMI medium. Purity was more than 95%. For microRNA analysis, correct amounts of cells were washed in PBS and snap frozen on dry ice. They were stored at À80°C until further analyses were performed.
T cell expansion. Sorted cells were cultured in complete RPMI medium and stimulated with CD3/CD28 beads (Dynabeads Human T-activator, Invitrogen, Life Technologies, Paisley, UK) at a bead-to-cell ratio of 4:1 for nTreg cells and 1:1 for conventional control T cells. Cells were seeded as 10,000 cells/100 ll in 96-well round bottom plates [13] . For expansion of Treg cells, 300 U/ml human IL-2 (Proleukin, Novartis Pharma GmbH, N€ urnberg, Germany) was added. On days 4, 11 and 18, cells were feed with complete RPMI supplemented with IL-2 for tTreg. On days 7 and 14, beads were removed by placement in a magnet and cells were restimulated with fresh beads and seeded into 24-well plates. The bead-to-cell ratio was now changed to 1:1 for nTreg cells and 1:10 for conventional T cells. On day 14-21, cells were harvested, washed in PBS and snap frozen on dry ice with 1 9 10 6 /tube. They were stored at À80°C until further analyses were performed. RNA purification. Total RNA from different sorted cell fractions and expanded cultures was extracted using the Trizol RNA isolation protocol as outlined by the manufacturer (Invitrogen).
Microarray analysis and statistical analysis. In an initial screening for differential expression of microRNAs in CD4 + CD25 + CD127lo tTreg cells and CD4 + CD25loCD127hi na€ ıve T cells, total RNA from two different donors was mixed from each of the two cell populations. The microarray analysis was essentially performed as previously described [16] . In brief, two micrograms of total RNA were labelled with Hy5 for CD4 + CD25 + CD127lo tTreg and Hy3 for CD4 + CD25loCD127hi na€ ıve T cells and vice versa using the miRCURY LNA Array Hi-Power labeling kit (Exiqon, Vedbaek, Denmark). The labelled RNA samples were mixed prior to hybridization to the microarray using the miRCURY LNA microRNA array (Exiqon) corresponding to version 11 of the Sanger miRBase. Following hybridization and washes in an HS-400-Pro microarray hybridization station (Tecan, Gr€ odig, Austria) according to the manufacturer's instructions, the dried slides were scanned in an ArrayWoRx white-light CCD-based scanner (Applied Precision, Issaquah, WA, USA) at a 10 lm resolution. The resulting images were imported into ImaGene 8.0 (BioDiscovery, El Segundo, CA, USA) where spot intensities and background measurements were calculated. To identify differentially expressed miRNAs in mDC compared to imDC, a ratio analysis was conducted using GeneSight-Lite 4.1.6 (BioDiscovery). Ratio values from all experiments were compiled using division by mean signal normalization. Prior to statistical analysis, ratio values were log 2 -transformed and significance analysis of microarray (SAM) was conducted on the data selecting only the miRNAs capable of fulfilling the criteria of a false discovery rate (FDR) of 0%.
Real-time PCR analysis and statistical analysis. Differential expression of selected miRNAs and mRNAs was determined using the TaqMan MicroRNA Assays (Applied Biosystems, Waltham, MA, USA) and the TaqMan Gene Expression Assays (Applied Biosystem, CA), respectively. For miRNA real-time PCR, the TaqMan microRNA Reverse Transcription kit (Applied Biosystems) and the TaqMan Universal PCR Master Mix (Applied Biosystems) were used to initially synthesize cDNA using 10 ng of total RNA by using the looped primers of the TaqMan MicroRNA Assay. The samples were set up on the ABI StepOne Plus real-time PCR machine (Applied Biosystems) in a 96-well plate at 16°C for 30 min followed by 42°C for 30 min and 85°C for 5 min. Each cDNA generated was subsequently amplified by real-time PCR using the sequence-specific primers from the TaqMan MicroRNA Assay. For mRNA real-time PCR, the TaqMan RNA-to-Ct 1-Step kit (Applied Biosystems) was employed using 10 ng of total RNA as input and including the sequence-specific primers and probes from the TaqMan Gene Expression Assays. Real-time PCR was performed using the standard TaqMan Assays protocol for 1-step RNA-to-Ct reactions on the ABI StepOne Plus real-time PCR machine (Applied Biosystems). The reactions were incubated in a 96-well plate at 48°C for 15 minutes, 95°C for 10 minutes followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. Each sample was analysed in triplicate in up to three independent repetitions. The level of miRNA and mRNA was measured using Ct (threshold cycle) according to the DCt method described by Livak and Schmittgen [17] . To normalize the relative abundance of both miRNAs and mRNAs, GAPDH mRNA was used as endogenous control. For each donor enrolled in the study, the relative abundance of the different targets was subsequently calculated as the 2 ÀDCt value, which provides an estimate of the expression level of the individual targets relative to the endogenous GAPDH gene expression level between the different cell populations of the specific donor. To compare expression levels between different donors, the expression levels of different cell populations for each donor were normalized by dividing the expression level in the individual cell populations with the average of the expression level of all cell populations for the individual donor for each target of interest. These values were then depicted in vertical scatter plots, and a statistical analysis using a paired t-test (two-tailed) to determine statistical significance (P < 0.05) was performed using the GraphPad Prism software.
Real-time PCR analysis directly on cells. To perform realtime PCR analysis on samples where only limited number of cells (10,000) could be obtained during sorting, we implemented the TaqMan MicroRNA Cells-to-Ct and the TaqMan Gene Expression Cells-to-Ct kits (Applied Biosystems) and procedures. Essentially, these analyses were performed the same way as described in the previous section; however, prior to the cDNA synthesis and realtime PCR analyses, a cell lysis step was included, involving spinning down cells (10,000) in 1.5-ml Eppendorf tubes, washing the cells in 50 ll 1xPBS at 4°C. PBS was removed by spinning, 5 ll of fresh 1 9 PBS was added and 50 ll of Lysis Solution (from the kits) was added. Cells were incubated for 5-8 min at room temperature (RT), and after that, 5 ll of Stop Solution (from the kit) was added and left after mixing for 2 min at RT. After this step, 5 ll of the lysate was used for miRNA analysis, and 10 ll was used mRNA analysis according to the procedures described above. À CD127hi T cell populations was analysed on a miRCURY LNA microRNA array corresponding to version 11 of the Sanger miRBase. Based on the statistical analysis of the established microarray data, the expression patterns of miR-146a and miR-142-3p represented two of the most prominently differentially expressed miRNAs in the two cell populations. The miR-146a microRNA was clearly expressed in higher levels in tTregs compared to na€ ıve conventional CD4 + T cells, whereas miRNA-142-3p, although highly expressed in both populations, was reduced in tTregs compared to na€ ıve conventional CD4 + T cells (Fig. 3) . Based on these array data, several other miRNAs were expressed in higher or lower levels in tTregs as compared to conventional CD4 + T cells (data not shown). However, expression of several of these could not be confirmed using qPCR for validation. Thus, as miR146a and miR-142-3p showed high expression validated with qPCR and array data suggested differential expression between T cell subsets, these two miRNAs were chosen for additional analysis. Similar to the observations for FOXP3 and Helios, sorted tTregs expressed higher levels of miR146a as compared to non-Treg CD4 + T cells including na€ ıve conventional T cells (Fig. 4) . In contrast, miR-142-3p expression was expressed at lower levels in tTregs, but was in general more similar between the cell subsets analysed. Thus, these data indicate that the differential expression of miR-146a and 142-3p could be applied as a miRNA tTreg-specific cellular marker combination.
Results

Expression
Differential expression of FOXP3, Helios and microRNAs in expanded tTreg cells versus expanded conventional T cells
Due to the low numbers in peripheral blood, expansion of tTregs cells is usually necessary when this cell type is used in immunopharmacological assays or as a cytotherapy in chronic inflammatory disorders. On the other hand, there is concern about a change in phenotype and function resulting from the in vitro expansion [3] . Thus, identification of markers that are stable and discriminative for tTreg cells is important for the validation of this cell type also during expansion for both in vitro studies and use in clinical cytotherapies. Indeed, there has recently been a debate on which subtype of Treg is most appropriate to expand. Based on CD45RA expression, tTregs can be distinguished as either CD4 + CD25hi CD127lowCD45RA + na€ ıve or CD4 + CD25hiCD127lowCD45RA-activated tTregs (Fig. 5) . Here, we isolated these two subtypes together with conventional T cells and expanded the different subsets in vitro using 2-3 weeks expansion with anti-CD3/ CD28 beads and IL-2. The cells expanded from the na€ ıve tTreg precursors still showed higher FOXP3 expression after 2-3 weeks in vitro expansion as compared to cells expanded from activated tTregs, but FOXP3 also remained higher in cells expanded from activated tTregs as compared to cells expanded from conventional T cells (Fig. 6) . Similar to the findings from Hoffman et al. [3] who observed particularly high variation of FOXP3 in expanded activated tTregs, the expression of FOXP3 was high but variable in all expanded Treg cell types in our hands but lowest in expanded activated tTregs (Fig. 6) . Also, Helios expression remained highest in cells expanded from na€ ıve Treg cells as compared to cells expanded from activated tTreg cells or conventional T cells (Fig. 6) . We then analysed the expression of miR-146a and 142-3p in expanded cell populations (Fig. 7) . Although levels of miR-146a and miR-142-3p expression were conserved after expansion, the expression was similar in all cells expanded from na€ ıve or activated tTregs or conventional T cells and could therefore not be used to discriminate tTreg from non-Treg in expanded cell populations. Thus, expression of FOXP3 and Helios was still superior in discriminating these cell subsets after expansion (Figs 7  and 8 ).
Differential expression of FOXP3, Helios and microRNAs in freshly isolated na€ ıve vs activated tTregs
Finally, we aimed at analysing FOXP3, Helios and the two miRNAs in freshly isolated na€ ıve vs activated tTregs to test whether the two miRNAs could discriminate these cell subsets prior to expansion. With the low number of tTregs in peripheral blood, it is difficult to obtain sufficient number of cell subsets like na€ ıve vs activated tTregs for such analysis. We therefore applied a method for qPCR on low number of cells based on integrating cell lysis, cDNA synthesis and real-time PCR (Cell-to-Ct qPCR) into one procedure allowing us to analyse 10,000 cells directly. We analysed the expression of FOXP3, Helios, miR-146a and miR-142-3p in freshly isolated na€ ıve tTregs vs activated tTregs based on the sorting strategy shown in Fig. 9A . The qPCR data provided evidence that the expression of all four markers, FOXP3, Helios, miR-146a and miR-142-3p, was significantly downregulated in activated vs na€ ıve tTregs (Fig. 9B) . À /CD25int. *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 ........................................................................................................................................................... .... 
CD25hiCD127lowCD45RA
À and (3) na€ ıve tTreg cells: CD4 + CD25hi CD127lowCD45RA + . *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001. 
Discussion
The identification of human tTreg cells is still based on only few markers, which at the same time are also expressed in a few other T cell subset under various conditions. Thus, miRNAs may be a novel molecular family from which a specific fingerprint of the tTreg subset can be identified. At the same time, definition of ............................................................................................................................................................... cellular markers that are stable in tTregs during in vitro expansion is necessary for several novel applications of this cell type including cytotherapies and immunopharmacological assays. In relation to this, we here analysed the miRNA profile of tTreg and non-Treg T cell subsets and compared the expression of potentially identified miRNA miR-146a and 142-3p with conventional markers such as FOXP3 and Helios.
Adoptive transfer of CD4(+)CD25(+)FOXP3(+) regulatory T cells (Treg) is a novel and promising therapy for autoimmune and inflammatory diseases, but for such therapy large numbers of Treg cells are required and therefore methods for expansion of human Treg cells must be applied [18] . For this purpose, a few other studies have identified CD4(+)CD25(high)CD45RA(+) T cells as the optimal Treg subset for expansion [15, 19] . Indeed, other subsets like activated tTregs may instead differentiate into effector T cells [20] . The same concerns relate to the use of expanded tTregs in in vitro immunopharmaceutical assays aimed at analysing the effect of novel immunomodulators [13] . Here, we confirm the instability of FOXP3 expression in in vitro-expanded activated Tregs and also demonstrate the loss of Helios expression. In addition, tTreg prevalent expression of miR-146a and 142-3p is changed, and these miRNAs instead become equally expressed in different T cell subsets.
In our study, levels of FOXP3, Helios, miR-146a and miR-142-3p were significantly reduced in freshly sorted activated tTregs as opposed to na€ ıve tTregs. However, it is still of interest that miR-146 and 142-3p expression is selective for na€ ıve tTregs prior to expansion. This is due to the need for additional Treg markers as FOXP3 may also be temporarily expressed in, for example, activated conventional T cells. Of interest, others have recently used similar approaches [4] and also identified increased expression of miR-146a in Treg cells together with miR-21 and let-7 g together with decreased expression for miR-125a compared to conventional T cells among other potential candidates.
The function of miRNAs in Treg immunobiology has only recently been discovered. Several miRNAs seem implicated; for example, miR-15b/16, miR-24 and miR29a have been shown to regulate induction of Tregs from na€ ıve CD4 + T cells [7] . Little is known about miR-146a in human Tregs, but a recent paper demonstrated that this miRNA together with miR-155 may influence the Treg phenotype [10] . Another recent paper on mouse Tregs similarly demonstrated that miR-146a is prevalently expressed in Tregs and important for their suppressive function through regulation of STAT1 activity and response to SOCS1-mediated negative regulation of STAT1 [8] . Similar pathways linking Treg function and expressed miRNAs were shown by Lu et al. [9] who demonstrated the ability of FOXP3 in mice to induce high miR-155 levels which subsequently controlled IL-2 responsiveness again through SOCS1 involvement. Finally, miR-142-3p has also from mouse studies been shown to be involved in regulation of Treg function through targeting of adenylyl cyclase and therefore inhibition of cAMP levels. The mechanisms of this were further shown to be regulated by FOXP3 which downregulate miR-142-3p to ensure high cAMP in Tregs which is necessary for the suppressive function [21] . This is in line with the reduced levels of miR-142-3p we demonstrated in Tregs as opposed to non-Tregs.
In conclusion, we identified selective expression of FOXP3, Helios in tTregs combined with elevated miR146a and reduced miR-142-3p as compared to other T cell subsets. In freshly sorted activated tTregs, FOXP3 levels were reduced as compared to na€ ıve Tregs, but miR-146a levels were increased. However, after expansion of Tregs, miR-146a and miR-142-3p were less prevalently expressed in Tregs cells as compared to other T cell subsets, whereas FOXP3 levels were reduced after expansion. These data confirm the use of miR-146a and miR-142-3p as markers of n€ aive tTregs and the observation on phenotypical change after in vitro expansion has implication for the use of expanded Tregs in cytotherapies and immunopharmacological assays.
